A Phase 2 interventional study of Non-invasive ventilation in Amyotrophic Lateral Sclerosis (ALS), Chronic Respiratory Failure and Neuromuscular Disease Patients, sponsored by University of Pennsylvania. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-26.
Sponsored by University of Pennsylvania · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.
Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 126th largest by planned enrollment of the 307 interventional ones that give a count, is one of 33 that started in 2026, is one of 89 in phase 2, reaches primary completion later than 96 of the 128 other live ones, and was the 393rd registered.
981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18–80
Cognixion · Sites in United States
Ages 18+
Johns Hopkins University · Sites in United States
Ages 18+ · Healthy volunteers
Neuralink Corp · Sites in United States
Ages 18+
Biogen · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
440 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 89 · Phase 2 139 · Phase 3 48 · Phase 4 1
First in 1982; this study’s year is marked. 33 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 48 is above the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 33 across the 307 interventional studies, 100 across the 121 observational. Of the 277 that completed or were terminated, 102 (37%) have results posted.
This tab as a report to print or save as PDF → With an account.
163 of 440 have an industry lead sponsor. The 10 most frequent:
University of Pennsylvania is the lead sponsor of 1,668 studies on the registry; 229 are open to participants now.
Of its 160 completed or terminated interventional studies of FDA-regulated products, 110 (69%) have results posted.
University of Pennsylvania has 4 studies filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
41 of the studies in Amyotrophic Lateral Sclerosis with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07161999Phase 3Coya TherapeuticsStudy of COYA 302 for the Treatment of ALS | 2027-04 |
| NCT04057898Phase 3MediciNovaEvaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS | 2027-04 |
| NCT04297683Phase 3Merit E. Cudkowicz, MDHEALEY ALS Platform Trial - Master Protocol | 2027-07 |
| NCT07410806Phase 3Merit E. Cudkowicz, MDHEALEY ALS Platform Trial - Regimen I NUZ-001 | 2027-07-01 |
| NCT04220190Phase 3Rapa Therapeutics LLCRAPA-501 Therapy for ALS | 2027-07-01 |
Add all 41 to your calendar (.ics) → With an account.
Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Amyotrophic lateral sclerosis (ALS) is a disease that causes weakness of the muscles of the body. The disease can eventually lead to severe breathing problems, which is the most common cause of death from ALS. The treatment for breathing is non-invasive ventilation (NIV). It is a machine that helps a person breathe by pushing air in and out of their lungs through a mask worn over the face. Research has shown that NIV can improve the quality of life and survival of someone with ALS. Unfortunately, NIV is not equally beneficial for everyone. The investigators do not yet know the best time or method for starting NIV in ALS. Europe and Canada allow starting NIV much earlier in ALS than the United States. Current recommendations for starting NIV are based on the opinion of experts rather than large research studies. Medical insurance companies will not cover NIV until significant breathing weakness occurs. After NIV is started, there is no evidence-based guidance on the best way to adjust NIV to benefit patients as much as possible. Some patients have difficulty tolerating NIV, but it is not clear how to identify these individuals ahead of time.
The investigators have created a new prediction tool that can identify patients at high risk of breathing problems within the next 6 months. This may help the study team identify who is more likely to benefit from starting NIV early. The investigators have published a paper that shows that NIV helps people with ALS live longer. This paper also showed that patients get more benefit with use NIV for at least 4 hours per day. The investigators published another paper that measured a gas called carbon dioxide (CO2), which goes high if someone's breathing is weakened. This paper showed that patients with ALS may live longer when CO2 levels are lowered using NIV. The investigators also have data suggesting that certain characteristics may predict who is less likely to use NIV at least 4 hours per day.
In this study, the investigators will collect pilot data on starting early NIV in individuals with ALS who do not yet meet insurance criteria for covering NIV. The research team will first use their previously published prediction tool to identify patient risk. Then, subjects would be randomized to start early NIV or to usual care. The usual care group would eventually start NIV as would occur if the participants were not in the study.
The purpose of this study is to collect data to help the investigators plan a larger randomized clinical trial. This study has 4 objectives. First, the project aims to identify individuals who would benefit from earlier NIV. The research team will use the original prediction tool to identify risk of severe breathing problems within the next 6 months. Second, the project aims to show that it is feasible to start NIV early. Third, the project aims to gather data on the effect of randomization on symptoms, CO2 levels, and outcomes. Fourth, the project aims to identify traits that may make someone less likely to use NIV.
Background: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease with high morbidity and universal mortality predominantly due to respiratory failure. Non-invasive ventilation (NIV) improves quality of life (QoL) and extends survival in ALS beyond any medication.1-3 However, the best timing for NIV initiation is based only on expert opinion.4,5 For example, clinicians in the United States initiate NIV much later than European or Canadian guidelines,4,6,7 as payers do not cover NIV until significant respiratory impairment occurs. While potentially beneficial, early NIV initiation could increase burden for patients due to mask intolerance, claustrophobia, and disturbed sleep, possibly negating any clinical benefit. Similarly, there are no surrogate endpoints to guide NIV settings and mask selection. Thus, clinicians employ generic approaches despite significant disease heterogeneity. Given the variable onset and progression of ALS, strategies for anticipating respiratory risk and personalizing NIV management are critical to maximize NIV benefit while reducing its burden.
The investigators' ultimate goal is to conduct Phase III multicenter clinical trials which investigate early NIV strategies to improve quality of life and survival in individuals with ALS. Before embarking on a large RCT of early NIV in ALS, it is necessary to collect pilot data on feasibility, effect sizes, and personal factors associated with NIV usage. The study team's prior work has developed a novel clinical prediction tool which can stratify ALS patients at presentation into high versus low risk of respiratory insufficiency within 6 months, capable of identifying an enriched subgroup suitable for an interventional study. The investigators have performed semi-structured interviews which suggest that ALS patients value being proactive about their respiratory care. The investigators have shown that improving transcutaneous carbon dioxide (CO2) levels is associated with improved survival in ALS, suggesting that transcutaneous CO2 could be a surrogate endpoint for guiding NIV management. The investigators also have found that factors at time of NIV initiation, such as ALSFRS-R speech and dyspnea scores, are significantly associated with NIV adherence.
Clinical Intervention: In this RCT of patients who have yet to meet insurance criteria for NIV coverage, the research team will randomize individuals to early NIV versus usual care, stratified by 6-month risk of respiratory insufficiency as determined by the investigators' previously published novel clinical prediction tool.
Objective(s): The objectives in this pilot study are to collect: 1) feasibility data on randomization to early NIV; 2) estimates of effect sizes of early NIV versus usual care on endpoints such as QoL, transcutaneous CO2, symptoms, and survival; and 3) identify factors present at time of NIV initiation which predispose to low hourly usage of NIV. The research team will analyze results across randomization groups, as well as assess the interaction between randomization and predicted risk of respiratory insufficiency.
Study Design: This study will be a 3-center phase II pilot randomized clinical trial of incident ALS patients diagnosed in the last 6 months.
Clinical Impact: The proposed study will help the investigators understand the feasibility and safety of starting early NIV in ALS. The study team will assess effect sizes on clinical endpoints, which will be critical for planning a future large RCT. Lastly, the study team will learn about patient characteristics that may predispose to lower NIV adherence. The investigators will examine results across randomization and the interaction with predicted risk of respiratory insufficiency. Leveraging the clinical prediction tool may help identify an enriched patient population suitable for future interventional studies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Current or prior or recommended/prescribed use of NIV including:
i) bi-level positive pressure ventilation, such as a respiratory assist device or home ventilator ii) Current or prior use of continuous positive airway pressure, or "CPAP" therapy
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to this arm will be assigned to start therapy with non-invasive ventilation.
Device: Non-invasive ventilation
Participants randomized to this arm will receive usual care for amyotrophic lateral sclerosis.
Non-invasive ventilation will be started earlier than usual respiratory care guidelines for ALS in the United States.
Also known as: non-invasive positive pressure ventilation, bilevel positive airway pressure
Time to first use of non-invasive ventilation
Number of days between randomization to first recorded overnight usage of non-invasive ventilation according to ventilation device data download.
Time frame: From enrollment to end of follow-up at approximately 1 year
Quality of life questionnaire
Quality of life will be measured by the ALS Specific Quality of Life questionnaire - short form (ALSSQOL-SF), a validated questionnaire to assess quality of life in terms applicable to a person with ALS. The questionnaire includes 20 questions scored on a scale of 0-10.
Time frame: From enrollment to completion of follow-up at approximately 1 year
Transcutaneous carbon dioxide
Measured during the day in clinic using a transcutaneous carbon dioxide monitor. Units are in mmHg
Time frame: From enrollment to end of follow-up at approximately 1 year
Oxygen saturation using pulse oximetry
Pulse oximeter used during the day during a clinic visit. Unites in % of saturated hemoglobin.
Time frame: From enrollment to completion of follow-up at approximately 1 year
Epworth Sleepiness Scale - Alternative (ESS-ALT) questionnaire
The ESS-ALT includes 8 questions on likelihood of falling asleep during various activities and was designed for individuals with physical disabilities. Each question is rated on an ordinal integer scale of 0 (never) to 3 (high).
Time frame: From enrollment to completion of follow-up at approximately 1 year.
ALS Functional Rating Scale - Revised (ALSFRS-R) scores
The ALSFRS-R is a 12-item standardized questionnaire to assess the motor function status of an individual with ALS. Each of the 12 components of the questionnaire are scored on a scale of 0 to 4, with 4 being normal/no symptoms at all and 0 being severely symptomatic with little or no function.
Time frame: From enrollment to completion of follow-up at approximately 1 year.
Karolinska Sleepiness Scale (KSS)
The KSS questionnaire includes 1 question that is a 9-point ordinal integer scale asking the sleepiness level in the immediately preceding 10 minutes. The scale ranges from 1 (extremely alert) to 9 (very sleepy, great effort to keep awake, fighting sleep).
Time frame: From enrollment to completion of follow-up at approximately 1 year.
Global rate of change of breathing questionnaire
The global rate of change score for breathing will obtain a participant's subjective sense of their breathing status. The global rate of change score for the breathing will ask patients how their breathing is today by rating it on a Likert scale from -7 (extremely impaired) to +7 (extremely strong).
Time frame: From enrollment to completion of follow-up at approximately 1 year.
Global rate of change of sleep quality
The global rate of change score for sleep quality will obtain a participant's subjective sense of their sleep quality. The global rate of change score for the sleep quality will ask patients how their sleep quality is today by rating it on a Likert scale from -7 (extremely poor) to +7 (extremely good).
Time frame: From enrollment to completion of follow-up at approximately 1 year.
Tracheostomy-free survival time
Number of days between enrollment and the end of follow up, study withdrawal, or death without interval placement of a tracheostomy.
Time frame: Time in days between enrollment and either study withdrawal, death, placement of a tracheostomy, or completion of follow-up at approximately 1 year.
Hospitalizations
Number and time to hospitalizations during follow-up.
Time frame: From enrollment to completion of follow-up at approximately 1 year.
Average daily hourly usage of NIV
This will be collected on subjects who are prescribed NIV within either study arm. Defined using telemonitoring portal data downloads (such as ResMed AirView for ResMed devices) which summarize average daily hourly usage over various specified time interval (e.g., the previous 30 days).
Time frame: Between enrollment and completion of follow-up at approximately 1 year.
Vital capacity
Measured by performing a spirometry maneuver for vital capacity using a hand-held clinical-research grade spirometer in the sitting and upright position. Units are in liters.
Time frame: From enrollment to completion of follow-up at approximately 1 year.
Maximal inspiratory pressure
Measured using a hand-held digital manometer with the patient in the sitting and upright position.
Time frame: From enrollment to completion of follow-up at approximately 1 year.
Plan to share: Yes — Data dictionary and de-identified dataset
Supporting information: Study protocol, Informed consent form, Analytic code
Time frame: Upon study completion and for up to 3 years after study end date.
Access criteria: De-identified data available upon completion of a data sharing agreement
Started Jun 2026 (actual). Primary completion is estimated for May 2029, 35 months after the start.
Of 37 non-industry phase 2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 41. This study's planned 35 months is close to that.
Counting every sponsor, half of 73 studies reached it within 24 months; a quarter within 16 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amyotrophic Lateral Sclerosis →